Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 29Gemcitabine 16Cyclophosphamide 14Nivolumab 12Carboplatin 12Capecitabine 11Trastuzumab 9Paclitaxel 9Magnetic Resonance Spectroscopy 8Irinotecan 8Bevacizumab 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8olaparib 7fludarabine 7Docetaxel 7spartalizumab 6aldesleukin 6Drug Therapy 6Cisplatin 6durvalumab 5atezolizumab 5Standard of Care 5Specimen Handling 5Oxaliplatin 5Biopsy 5sargramostim 4palbociclib 4niraparib 4enzalutamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × parsaclisib × Breast × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡